Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Boots parent company appoints permanent CEO at 'pivotal time'

Tim Wentworth will replace Ginger Graham, who was appointed interim Walgreens Boots Alliance (WBA) chief executive last month, the company has announced.  

Boots parent company WBA this week (October 10) announced that Tim Wentworth has been appointed the company’s new chief executive, effective from October 23.

Rosalind Brewer previously held the position before stepping down from the role and the company’s board at the end of August.

Long-time WBA board member Ginger Graham took over the role on an interim basis after Ms Brewer’s departure.

But WBA said this week that after Mr Wentworth joins the company and its board of directors, Ms Brewer will act as the board’s “lead independent director”.

It added that he joins the company at a “pivotal time” as it “focuses on right-sizing the business, while…creating greater value for employees, patients, customers and shareholders”.

 

“The next phase of WBA’s evolution”

 

Mr Wentworth – who “brings nearly three decades of healthcare leadership experience” - will join WBA after founding health services organisation Evernorth and working as chief executive at Express Scripts - the largest pharmacy benefit manager in the United States.

He has also worked at medical report provider Medco, multi-level marketing company Mary Kay and beverage company PepsiCo.

Mr Wentworth said he was “honoured and excited” to “lead the next phase of WBA’s evolution” and “deliver sustainable value and results”.

He said that he believes WBA “is well-positioned to deliver more personalised, coordinated care and achieve better outcomes at a lower cost” despite “the challenges that health plans, healthcare providers, pharmacies and retailers are confronting today”.

“I believe in WBA’s vision to be the leading partner in reimagining local healthcare and wellbeing for all,” he added.

WBA’s executive chairman Stefano Pessina said he was “[looking] forward to working with” Mr Wentworth, who he said would “lead WBA into a successful future”.

He also thanked Ms Graham “for her leadership and immense commitment…during this interim period”.

He added that the board is “confident” that Mr Wentworth “is the right person to lead WBA’s next phase of growth into a customer-centric healthcare company”.

 

Sale rumours

 

The news comes after Boots revealed plans to close 300 branches where they are located “in close proximity to each other” in June, with closures starting the following month.

This followed a report by pharmacy sales specialists Hutchings that claimed that WBA is “in the throes of undertaking a strategic review of Boots pharmacies, possibly with an eye to a future sale”.

Hutchings claimed that “private equity investors are rumoured to be potential suitors”.

At the time, a Boots spokesperson told C+D that “nothing [had] changed” since June 2022, when WBA announced its decision to keep Boots under its ownership.

Related Content

Topics

         
Pharmacist
Norfolk
£53,025

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD137334

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel